Open Access
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2018; 39(01): 23-27
DOI: 10.4103/ijmpo.ijmpo_126_16
Original Article

Renal Cell Cancer: Clinicopathological Profile and Survival Outcomes

Priya Tiwari
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Lalit Kumar
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Geetika Singh
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India
,
Amlesh Seth
Department of Urology, All India Institute of Medical Sciences, New Delhi, India
,
Sanjay Thulkar
Department of Radiology, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations

Financial support and sponsorship Nil.
Preview

Abstract

Background: The incidence of renal cell cancer (RCC) is increasing worldwide. However, scant information is available from the Indian subcontinent regarding its clinicopathological characteristics and survival outcomes. We retrospectively analyzed data of patients suffering from RCC at our center over the last one decade (2004–2013) to generate information on these aspects. Materials and Methods: Case records of 423 patients treated between 2004 and 2013 were retrospectively analyzed. Baseline characteristics, histopathological information, and survival outcomes were assessed. Overall survival was calculated from the time of diagnosis to death due to any cause. Results: The median age was 52 years (range: 18–87 years). Male: female ratio was 3.5:1. The median duration of symptoms was 3 months (range: 0–24 months). Thirty-five patients (8.3%) were detected in asymptomatic state. The most common symptom was hematuria (53.2%) followed by flank pain (46.3%). The most common histology was clear cell subtype (71.4%). Two hundred and ninety-three (69.3%) patients presented with nonmetastatic disease whereas 130 (30.7%) had upfront metastatic disease. Five-year survival in Stages 1, 2, 3, and 4 was 92.7%, 72.9%, 54.6%, and 11.5%, respectively. Conclusion: Younger age, higher male–female ratio, lower proportion of asymptomatic patients, higher proportion of advanced stage at diagnosis, and lower stage-wise survival were some of the key findings.



Publication History

Article published online:
23 June 2021

© 2018. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India